Novartis’s investigational oral therapy for asthma fell at the first Phase III hurdle but pivotal studies in severe disease will be key to prospects.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced January-February 2016.

UK-based Redx Pharma has promoted Dr Richard Armer to chief scientific officer and Phil Tottey to chief financial officer.

The pharmaceutical division of Teijin has acquired rights in Japan to Pulmagen Therapeutics' lead CRTh2 antagonist ADC3680, which it will develop initially for bronchial asthma.